Osteonecrose dos Maxilares Relacionada a Medicamentos em Pacientes Oncológicos em um Hospital Escola no Sul do Brasil: Estudo Observacional Retrospectivo

Denyson Reinaldo  Xisto da Silva; Beatriz Farias Vogt; Mônica Cristina Bogoni Savian; Cleusa Marfisa Guimarães Jaccottet

doi:10.32635/2176-9745.RBC.2026v72n4.5802

Authors

Denyson Reinaldo Xisto da Silva Universidade Federal de Pelotas (UFPel). Pelotas (RS), Brasil. https://orcid.org/0000-0002-4411-6684
Beatriz Farias Vogt Universidade Federal de Pelotas (UFPel). Hospitais Universitários Federais, Hospital Escola (HE). Pelotas (RS), Brasil https://orcid.org/0000-0002-4033-2611
Mônica Cristina Bogoni Savian Universidade Federal de Pelotas (UFPel). Hospitais Universitários Federais, Hospital Escola (HE). Pelotas (RS), Brasil https://orcid.org/0000-0002-1428-330X
Cleusa Marfisa Guimarães Jaccottet Universidade Federal de Pelotas (UFPel). Hospitais Universitários Federais, Hospital Escola (HE). Pelotas (RS), Brasil https://orcid.org/0000-0003-2413-871X

DOI:

https://doi.org/10.32635/2176-9745.RBC.2026v72n4.5802

Keywords:

Bisphosphonate-Associated Osteonecrosis of the Jaw/drug therapy, Health Profile, Bone Density Conservation Agents, Zoledronic Acid

Abstract

Introduction: Medication-related osteonecrosis of the jaw is a serious adverse side effect associated with therapy with antiresorptive and antiangiogenic drugs. Objective: To describe the clinical and epidemiological profile of oncologic patients with medication-related osteonecrosis at the “Hospital Escola da Universidade Federal de Pelotas/HU BRASIL”. Method: Observational, retrospective, cross sectional study, utilizing a convenience sample, with data collected from electronic medical charts. Results: A total of 112 patients treated between 2017 and 2024 were evaluated, 56.25% (n=63) were women and 43.75% (n=49) were men. The mean age of the patients was 64.04 (SD: ± 12.19 years). The most frequent primary tumors sites were breast and prostate. Zoledronic acid (Zometa® 4mg) was the drug used by 94.64% (n=106) of the patients. The prevalence of osteonecrosis was 19.63% (n=22) and stage II was observed in 45.45% (n=10) of the sample. The most common triggering factor was tooth extraction, accounting for 50% (n=11) of the cases. Conclusion: Among patients with medication-related osteonecrosis, there was a predominance of individuals over 60 years of age, with men being the most affected. Advanced stages of the disease were the most frequent, zoledronic acid was the most commonly administered drug, and the evaluated risk factors did not show statistically significance associations.

Downloads

Download data is not yet available.

References

Marx RE. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7. doi: https://doi.gov/10.1016/s0278-2391(03)00720-1

Kim HW, Lee MW, Lee JH, et al. Comparison of the effect of oral versus intravenous bisphosphonate administration on osteoclastogenesis in advanced-stage medication-related osteonecrosis of the jaw patients. J Clin Med. 2021;10(13):2988. doi: https://doi.org/10.3390/jcm10132988

Gong X, Yu W, Zhao H, et al. Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs osteogenic activity. Sci Rep. 2017;7(36129). doi: https://doi.org/10.1038/srep36129

Kim JW, Kwak MK, Han JJ, et al. Medication related osteonecrosis of the jaw: 2021 position statement of the Korean society for bone and mineral research and the Korean association of oral and maxillofacial surgeons. J Bone Metab. 2021;28(4):279-96. doi: https://doi.org/10.11005/jbm.2021.28.4.279

Ruggiero SL, Dodson TB, Aghaloo T, et al. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. J Oral Maxillofac Surg. 2022;80(5):920-43. doi: https://doi.org/10.1016/j.joms.2022.02.008

Instituto Nacional de Câncer. Estimativa 2026: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2026 [acesso 2026 set 08]. Disponível em: https://ninho.inca.gov.br/jspui/bitstream/123456789/17914/1/Estima2026_completo%20%281%29.pdf

Goker F, Grecchi E, Grecchi F, et al. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci. 2021;25(6):2662-73. doi: https://doi.org/10.26355/eurrev_202103_25430

Bansal H. Medication-related osteonecrosis of the jaw: An update. Natl J Maxillofac Surg. 2022;13(1):5-10. doi: https://doi.org/10.4103/njms.NJMS_236_20

AlRowis R, Aldawood A, AlOtaibi M, et al. Medication-Related osteonecrosis of the jaw (MRONJ): A review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J. 2022;34(3):202-10. doi: https://doi.org/10.1016/j.sdentj.2022.01.003

Kuehn S, Scariot R, Elsalanty M. Medication-Related osteonecrosis: why the jawbone? Dent J (Basel). 2023;11(5):109. doi: https://doi.org/10.3390/dj11050109

Alsalih A, Dam A, Lindberg P, et al. Medication-Related osteonecrosis of the jaws initiated by zoledronic acid and potential pathophysiology. Dent J (Basel). 2021;9(8):85. doi: https://doi.org/10.3390/dj9080085

Otto S, Pautke C, Wyngaert TVD, et al. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-87. doi: https://doi.org/10.1016/j.ctrv.2018.06.007

Hospital Escola da Universidade Federal de Pelotas (HE UFPel). Plano Diretor Estratégico 2024-2028. Pelotas, RS. v. 02. 05 de maio de 2025 [acesso 2026 maio 25]. Disponível em: https://www.gov.br/hubrasil/pt-br/hospitais-universitarios/regiao-sul/he-ufpel/governanca/gestao-estrategica/plano-diretor-estrategico-he-ufpel-ebserh

Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13 [acesso 2026 03 12]; Seção I:59. Disponível em: https://www.gov.br/conselho-nacional-de-saude/pt-br/atos-normativos/resolucoes/2012/resolucao-no-466.pdf/view

Boston B, Ipe D, Capitanescu B, et al. Medication-related osteonecrosis of the jaw: a disease of significant importance for older patients. J Am Geriatr Soc. 2023;71(8):2640-52. doi: https://doi.org/10.1111/jgs.18414

Halpern LR, Adams DR. Treatment of medication-related osteonecrosis of the jaw: controversies in causality and therapy. Dent Clin North Am. 2023;68(1):67-85. doi: https://doi.org/10.1016/j.cden.2023.07.005

Carlos ACAM, Coelho LMC, Malta CEN, et al. Risk factors for bisphosphonate-related osteonecrosis of the jaws in bone metastatic breast and prostate cancer under zoledronate treatment: a retrospective analysis from 10 years of evaluation. Asian Pac J Cancer Prev. 2023;24(8):2681-9. doi: http://doi.org/10.31557/APJCP.2023.24.8.2681

Ferreira SS, Amaral JB, Pacheco JJ, et al. Osteonecrosis of the jaw associated with bisphosphonates infusion for treatment of plasma cell myeloma—a retrospective observational study of northern portuguese population. J Clin Med. 2024 May 2;13(9):2679. doi: https://doi.org/10.3390/jcm13092679

Rugani P, Walter C, Kirnbauer B, et al. Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma. Dent J (Basel). 2016;4(4):32. doi: https://doi.org/10.3390/dj4040032

Boffano P, Agnone AM, Neirotti F, et al. Epidemiology, etiopathogenesis, and management of MRONJ: a European multicenter study. J Stomatol Oral Maxillofac Surg. 2024;125(12 Suppl 2):101931. doi: https://doi.org/10.1016/j.jormas.2024.101931

Kang MH, Lee DK, Kim CW, et al. Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg. 2018;44(5):225-31. doi: https://doi.org/10.5125/jkaoms.2018.44.5.225

Pakdeemeechai S, Kammai J, Chaipattanawan N, et al. Medication-related osteonecrosis of the jaw in Northern Thailand: a one-year cohort study of risk factors, incidence, and healing outcomes. J Oral Biol Craniofac Res. 2025;15(6):1721-30. doi: https://doi.org/10.1016/j.jobcr.2025.10.008

Caldas RJ, Antunes HS, Pegoraro COR, et al. Oral health condition in cancer patients under bisphosphonate therapy. Support Care Cancer. 2021;29(12):7687-94. doi: https://doi.org/10.1007/s00520-021-06362-y

Lorenzo‐Pouso A, Pérez‐Sayáns M, Chamorro‐Petronacci C, et al. Association between periodontitis and medication‐related osteonecrosis of the jaw: a systematic review and meta‐analysis. J Oral Pathol Med. 2020;49(3). doi: https://doi.org/10.1111/jop.12963

Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of medication-related osteonecrosis of the jaw-a minireview. JBMR Plus. 2023;7(8):e10785. doi: https://doi.org/10.1002/jbm4.10785

Fusco V, Cabras M, Erovigni F, et al. A multicenter observational study on medication-related osteonecrosis of the jaw (MRONj) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. Med Oral Patol Oral Cir Bucal. 2021;26(4):e466-73. doi: https://doi.org/10.4317/medoral.24318

Bracchi P, Zecca E, Brunelli C, et al. A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab. Cancer Med. 2023;12(17):18317-26. doi: https://doi.org/10.1002/cam4.6429

Byrne H, O’Reilly S, Weadick CS, et al. How we manage medication-related osteonecrosis of the jaw. Eur J Med Res. 2024;29(1). doi: https://doi.org/10.1186/s40001-024-01912-6

Watanabe T, Asai K, Fukuhara S, et al. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: a subgroup analysis by disease stage. PLOS One. 2021;16(1):e0244859. doi: https://doi.org/10.1371/journal.pone.0244859

Bacci C, Cerrato A, Bardhi E, et al. A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities. Support Care Cancer. 2021;30(2):1723-9. doi: https://doi.org/10.1007/s00520-021-06587-x

Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws – Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40(4):303-9. doi: https://doi.org/10.1016/j.jcms.2011.05.003

Bedogni A, Mauceri R, Fusco V, et al. Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. 2024;30(6):3679-709. doi: https://doi.org/10.1111/odi.14887

Ministério da Saúde (BR), Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria. Nº 85, de 20 de dezembro de 2018. Torna pública a decisão de incorporar o ácido zoledrônico para doença de Paget no âmbito do Sistema Único de Saúde - SUS. Diário Oficial da União, Brasília, DF. 2018 dez 21 [acesso 2026 maio 25]; Seção I:830. Disponível em: https://www.gov.br/conitec/pt-br/midias/relatorios/portaria/2018/douportaria_-sctie_85_2018.pdf/@@display-file/file